FDA Will Mull OTC Smoking Cessation Long-Term Use As Support Builds
This article was originally published in The Tan Sheet
Executive Summary
Participants at an FDA workshop will consider issues that could influence whether the agency extends the use of nicotine-replacement therapies beyond the current 12-week indication
You may also be interested in...
FDA Ignores Tobacco Harm Reduction As Therapeutic Option – Experts
FDA's tobacco product policies impede development of alternatives to smoking-cessation products with utility for harm reduction, according to an expert panel.
FDA Ignores Tobacco Harm Reduction As Therapeutic Option – Experts
FDA's tobacco product policies impede development of alternatives to smoking-cessation products with utility for harm reduction, according to an expert panel.
FDA Ignores Tobacco Harm Reduction As Therapeutic Option – Experts
FDA's tobacco product policies impede development of alternatives to smoking-cessation products with utility for harm reduction, according to an expert panel.